SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001337553-22-000007
Filing Date
2022-02-24
Accepted
2022-02-24 16:16:34
Documents
13
Period of Report
2022-02-17
Items
Item 2.02: Results of Operations and Financial Condition
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K aeri-20220217.htm   iXBRL 8-K 47068
2 EX-99.1 aeri-4q21earningsreleaseex.htm EX-99.1 166094
  Complete submission text file 0001337553-22-000007.txt   367099

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT aeri-20220217.xsd EX-101.SCH 1936
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT aeri-20220217_lab.xml EX-101.LAB 24275
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT aeri-20220217_pre.xml EX-101.PRE 12664
7 EXTRACTED XBRL INSTANCE DOCUMENT aeri-20220217_htm.xml XML 10691
Mailing Address 4301 EMPEROR BOULEVARD SUITE 400 DURHAM NC 27703
Business Address 4301 EMPEROR BOULEVARD SUITE 400 DURHAM NC 27703 (919) 237-5300
AERIE PHARMACEUTICALS INC (Filer) CIK: 0001337553 (see all company filings)

IRS No.: 203109565 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36152 | Film No.: 22671183
SIC: 2836 Biological Products, (No Diagnostic Substances)